---

---

symbols : Azn   

save search

---

Global Orphan Drugs Market Research Report 2023: Market to Reach $415.2 Billion by the End of 2028 - Premium Pricing of Orphan Drugs and Increasing Collaborations/Licensing Agreements Bolsters Growth
Published: 2024-01-17 (Crawled : 20:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -7.6% | O: 0.1% H: 0.76% C: 0.76%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 4.7% | O: 1.06% H: 0.0% C: -2.34%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| -10.45% | O: 0.0% H: 0.0% C: 0.0%
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -19.1% | O: -0.6% H: 0.34% C: 0.34%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -8.68% | O: -0.78% H: 0.59% C: 0.57%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -6.62% | O: -0.21% H: 0.0% C: 0.0%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 4.63% | O: -0.54% H: 1.55% C: 1.33%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -8.87% | O: -1.1% H: 1.63% C: 1.59%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 6.94% | O: -0.51% H: 1.33% C: 0.93%
report reach research global growth market

---

Valo Health Announces Changes to its Board of Directors and Leadership Team
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 5.52% | O: 0.03% H: 0.75% C: 0.75%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -7.57% | O: -1.02% H: 0.0% C: 0.0%
NTLA | $21.16 -1.72% -1.75% 860K |

Health Technology

| -19.54% | O: -2.62% H: 2.9% C: -1.23%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 5.32% | O: -1.81% H: 0.63% C: 0.3%
health

---

AstraZeneca Plc Digital Transformation Strateg Report 2023: Technology Focus, Initiatives, Acquisitions, Partnership and Acquisition Network Map, ICT Budget, and Contracts
Published: 2024-01-12 (Crawled : 23:00) - prnewswire.com
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| Email alert Add to watchlist
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| Email alert Add to watchlist
partnership report astrazeneca acquisition network technology

---

Westpac Banking Corporation Digital Transformation Strategies Report 2023: Technology Focus, Initiatives, Venture Arm, Investments, Acquisitions, Partnerships, ICT Budget and Contracts
Published: 2024-01-12 (Crawled : 23:00) - prnewswire.com
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| Email alert Add to watchlist
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| Email alert Add to watchlist
WEBNF | $16.29 -11.38% 1.7K |

Finance

| Email alert Add to watchlist
report corporation technology

---

Anheuser-Busch InBev Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs
Published: 2024-01-12 (Crawled : 23:00) - prnewswire.com
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| Email alert Add to watchlist
BUD | $60.26 0.13% -0.45% 1.2M |

Consumer Non-Durables

| Email alert Add to watchlist
BUDFF | $59.7 -0.44% 190K |

Consumer Non-Durables

| Email alert Add to watchlist
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| Email alert Add to watchlist
WEBNF | $16.29 -11.38% 1.7K |

Finance

| Email alert Add to watchlist
report innovation

---

Advancing Melanoma Therapeutics: Global Market Insights and In-depth Analysis by BCC Research
Published: 2024-01-12 (Crawled : 11:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 2.39% | O: 2.07% H: 0.0% C: -0.06%
ERAS | $1.88 -2.59% -2.66% 530K |

| -1.03% | O: 0.0% H: 4.62% C: -1.03%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -8.12% | O: -0.16% H: 0.43% C: 0.02%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 2.41% | O: 0.25% H: 0.36% C: 0.1%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -9.75% | O: 0.71% H: 0.56% C: 0.42%
melanoma research global market

---

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 3.42% | O: 2.71% H: 0.36% C: 0.11%
LEXX | $2.18 -2.68% -2.75% 98K |

Health Technology

| 65.93% | O: 0.0% H: 8.15% C: 1.48%
PFE | News 4 | $26.27 -0.19% -0.15% 23M |

Health Technology

| -10.69% | O: -0.37% H: 1.09% C: 0.75%
NVO | News | $126.16 -1.93% -0.23% 3.1M |

Health Technology

| 21.38% | O: 0.19% H: 0.34% C: 0.21%
MRK | $127.0 0.1% -1.21% 7.1M |

Health Technology

| 8.24% | O: 0.32% H: 0.26% C: -0.18%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.61% | O: 0.28% H: 0.99% C: 0.93%

---

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Published: 2024-01-08 (Crawled : 12:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 3.42% | O: 2.71% H: 0.36% C: 0.11%
IONS | $42.455 1.47% 1.45% 730K |

Health Technology

| -17.48% | O: -0.3% H: 3.6% C: 3.5%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.61% | O: 0.28% H: 0.99% C: 0.93%
momentum pipeline key

---

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2024-01-08 (Crawled : 12:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| 30.86% | O: 2.29% H: 8.38% C: 4.47%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.61% | O: 0.28% H: 0.99% C: 0.93%
first million payment astrazeneca cancer trial milestone

---

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Published: 2024-01-05 (Crawled : 07:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K |

Health Technology

| -22.76% | O: 1.8% H: 0.0% C: -0.52%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 2.37% | O: 0.15% H: 1.88% C: -1.17%
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -21.31% | O: 2.32% H: 0.49% C: -1.46%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.01% | O: -0.68% H: 0.87% C: 0.1%
study

---

Cancer Immunotherapy Market to grow by USD 38.57 billion from 2022 to 2027, North America to account for 41% of market growth- Technavio
Published: 2024-01-04 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K |

Health Technology

| 0.1% | O: 2.46% H: 0.0% C: 0.0%
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -7.46% | O: 0.49% H: 0.6% C: -0.83%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 2.37% | O: 0.15% H: 1.88% C: -1.17%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| -8.57% | O: -0.24% H: 1.43% C: 1.43%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -6.36% | O: 0.32% H: 0.93% C: 0.38%
GSK | News | $40.86 -0.92% -0.15% 1.7M |

Health Technology

| 5.55% | O: -0.36% H: 0.98% C: 0.72%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -7.74% | O: -0.14% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 3.01% | O: -0.68% H: 0.87% C: 0.1%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -9.77% | O: -0.32% H: 0.44% C: 0.26%
america cancer immunotherapy market

---

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Published: 2024-01-02 (Crawled : 14:00) - prnewswire.com
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 5.2% | O: -0.76% H: 2.65% C: 2.33%
license astrazeneca global program therapeutics agreement

---

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
Published: 2023-12-26 (Crawled : 10:00) - biospace.com/
GRCL | $10.25 -0.29% 6.4M |

Manufacturing

| 59.92% | O: 54.84% H: 0.0% C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 7.18% | O: 3.01% H: 0.0% C: -0.33%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 6.88% | O: 0.32% H: 0.21% C: 0.0%
astrazeneca cell acquire therapy

---

Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -1.63% | O: 3.66% H: 0.0% C: -0.12%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 7.51% | O: 3.33% H: 0.0% C: -2.93%
NVO | News | $126.16 -1.93% -0.23% 3.1M |

Health Technology

| 24.31% | O: -0.31% H: 0.39% C: -0.44%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -2.51% | O: 1.09% H: 0.0% C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 29.2% | O: 0.18% H: 0.5% C: -0.46%
BMY | $48.86 -0.27% -0.02% 16M |

Health Technology

| -4.43% | O: -0.78% H: 5.15% C: 2.81%
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| 11.11% | O: 0.58% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -3.43% | O: 1.03% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K |

Health Technology

| 7.77% | O: 0.52% H: 0.58% C: 0.05%
GILD | $67.07 0.06% 0.06% 8.3M |

Health Technology

| -15.08% | O: 0.34% H: 1.02% C: 0.59%
BIIB | $201.91 4.52% 4.32% 3.3M |

Health Technology

| -23.9% | O: 0.57% H: 1.36% C: 1.04%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 6.86% | O: 1.06% H: 0.18% C: -1.06%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -2.07% | O: 0.24% H: 2.03% C: 1.49%
patent report global market

---

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
Published: 2023-12-21 (Crawled : 00:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 7.51% | O: 3.33% H: 0.0% C: -2.93%
IONS | $42.455 1.47% 1.45% 730K |

Health Technology

| -14.8% | O: 1.43% H: 3.87% C: 2.77%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 6.86% | O: 1.06% H: 0.18% C: -1.06%
granted approval treatment

---

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
SLRN | $4.57 -0.65% -0.66% 530K |

| -35.39% | O: 0.98% H: 0.9% C: -0.97%
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 7.0% | O: -0.0% H: 1.62% C: -0.47%
RYTM A | $39.71 -0.73% -0.73% 400K |

Health Technology

| -10.81% | O: 2.05% H: 0.69% C: -1.35%
NEO | $14.03 -0.92% -0.93% 540K |

Health Services

| -26.4% | O: 2.39% H: 5.33% C: 4.31%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 7.71% | O: 1.44% H: 0.22% C: -0.64%

---

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Published: 2023-12-19 (Crawled : 12:30) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| 213.7% | O: 178.08% H: 21.18% C: -1.48%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 7.43% | O: -0.5% H: 0.99% C: 0.43%
first payment astrazeneca cancer trial milestone

---

Proton Pump Inhibitors (PPIs) Market to grow by USD 807.89 million from 2023-2028 | North America to account for 36% of market growth - Technavio
Published: 2023-12-19 (Crawled : 07:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 9.61% | O: 3.81% H: 0.0% C: 0.0%
BHC | $8.56 0.35% 0.0% 2M |

Health Technology

| 15.74% | O: 1.22% H: 1.88% C: 0.94%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -2.87% | O: 0.45% H: 0.0% C: 0.0%
RDHL | $0.415 -2.99% -3.08% 190K |

Health Technology

| -64.75% | O: 0.82% H: 8.94% C: 7.32%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 7.43% | O: -0.5% H: 0.99% C: 0.43%
AMGN | News | $273.085 -0.17% -0.17% 2.5M |

Health Technology

| -0.7% | O: 1.17% H: 0.67% C: -0.09%
america growth market

---

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published: 2023-12-18 (Crawled : 00:00) - biospace.com/
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 9.34% | O: 1.03% H: 1.08% C: 0.73%
breast cancer trials plus initiated

---

Incretin-based Drugs Market to Reach $73.9 billion, globally, by 2032 at 7.9% CAGR: Allied Market Research
Published: 2023-12-15 (Crawled : 15:30) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K |

Health Technology

| 5.89% | O: -3.0% H: 2.15% C: 2.15%
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| -2.04% | O: 0.0% H: 0.0% C: 0.0%
NVO | News | $126.16 -1.93% -0.23% 3.1M |

Health Technology

| 31.27% | O: -0.48% H: 0.0% C: -0.44%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| -0.01% | O: -1.31% H: 0.56% C: -0.17%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 24.49% | O: -4.44% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -2.57% | O: -0.93% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M |

Health Technology

| 6.78% | O: -2.23% H: 0.28% C: -0.11%
reach research market

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---